Sage Therapeutics Inc. | Mutual Funds
Mutual Funds that own Sage Therapeutics Inc.
Fidelity Growth Company Fund
2,094,906
4.49%
-11,367
0.71%
07/31/2018
T Rowe Price Health Sciences Fund
1,856,661
3.98%
40,395
2.39%
06/30/2018
T Rowe Price New Horizons Fund
1,647,127
3.53%
36,102
1.11%
06/30/2018
Vanguard Total Stock Market Index Fund
1,112,032
2.38%
5,634
0.02%
07/31/2018
Vanguard Small Cap Index Fund
1,111,936
2.38%
14,595
0.19%
07/31/2018
BB Biotech AG
1,002,439
2.15%
-90,000
3.96%
03/31/2018
Hartford Mid Cap Fund
937,964
2%
16,318
1.15%
07/31/2018
Fidelity Select Biotechnology Portfolio
931,793
2%
0
1.67%
07/31/2018
Oppenheimer Global Fund
729,489
1.56%
0
1.02%
03/31/2018
Vanguard Small Cap Value Index Fund
698,557
1.5%
7,362
0.35%
07/31/2018
| Address |
215 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.sagerx.com |
| Updated |
07/08/2019 |
| SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |
